. Author manuscript; available in PMC: 2018 Jul 9.

Published in final edited form as: Clin Immunol. 2018 Mar 5;191:10–20. doi: 10.1016/j.clim.2018.03.002

Table 3.

NK-cell counts during and following treatment with tofacitinib.

	Cell count, cells/μL, median (range)

	Baseline	Day 15	Day 29	Day 14 post-treatment	Day 28 post-treatment
Total NK	213 (65–510)	144^*** (71–400)	142^*** (49–567)	151^*** (58–577)	161^† (74–561)
CD56 null NK	7.14 (2.76–20.86)	5.51 (1.74–30.42)	7.94 (2.37–29.50)	7.19 (2.54–19.62)	8.17^* (2.43–41.50)
CD56 dim NK	146 (36–405)	99^** (35–340)	94^** (27–410)	107^* (34–391)	127^†(45–422)
CD56 bright NK	51.0 (20.4–123.1)	36.3^** (13.1–88.0)	29.8^*** (13.9–148.1)	30.9^*** (12.7–167.4)	35.7^***^† (16.6–120.3)

Test statistics are based on log-transformed data.

CD, cluster of differentiation; NK, natural killer.

p < 0.05,

^**

p < 0.001,

^***

p< 0.0001 compared with baseline,

^†

p < 0.05 compared with Day 29.